Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting
As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors (other than breast cancer and gastric/gastroesophageal junction cancer) were enrolled, 92.3% of whom had received ≥2L prior systemic therapy. The objective response rate (ORR) was 53.8% with 6.8 months median duration of response (mDOR), 5.6 months median progression survival (mPFS) and […]